Market Closed -
Canadian Securities Exchange
14:33:42 2023-05-05 EDT
|
5-day change
|
1st Jan Change
|
0.13
CAD
|
-.--%
|
|
-.--%
|
-.--%
|
Fiscal Period: December |
2016
|
2017
|
2018
|
2019
|
2020
|
2021
|
---|
Capitalization
1 |
2.39
|
125.6
|
26.58
|
12.64
|
7.965
|
4.392
|
Enterprise Value (EV)
1 |
2.279
|
120.7
|
19.58
|
9.58
|
7.792
|
5.863
|
P/E ratio
|
-2.32
x
|
-27
x
|
-5
x
|
-6.38
x
|
-0.95
x
|
-0.85
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
-
|
65,603,718
x
|
1,888,158
x
|
EV / Revenue
|
-
|
-
|
-
|
-
|
64,179,919
x
|
2,520,327
x
|
EV / EBITDA
|
-3.18
x
|
-24.8
x
|
-
|
-7.44
x
|
-6.39
x
|
-1.2
x
|
EV / FCF
|
-12.4
x
|
74
x
|
16.6
x
|
187
x
|
-2.8
x
|
-36.3
x
|
FCF Yield
|
-8.05%
|
1.35%
|
6.02%
|
0.53%
|
-35.8%
|
-2.75%
|
Price to Book
|
-22.9
x
|
17.2
x
|
1.87
x
|
0.86
x
|
1.07
x
|
1.34
x
|
Nbr of stocks (in thousands)
|
3,983
|
7,610
|
9,845
|
10,532
|
10,620
|
10,712
|
Reference price
2 |
0.6000
|
16.50
|
2.700
|
1.200
|
0.7500
|
0.4100
|
Announcement Date
|
17-05-01
|
18-04-30
|
19-04-30
|
20-05-29
|
21-05-31
|
22-05-02
|
Fiscal Period: December |
2016
|
2017
|
2018
|
2019
|
2020
|
2021
|
---|
Net sales
|
-
|
-
|
-
|
-
|
0.1214
|
2.326
|
EBITDA
1 |
-0.7168
|
-4.865
|
-
|
-1.288
|
-1.22
|
-4.903
|
EBIT
1 |
-0.8425
|
-4.991
|
-5.455
|
-1.322
|
-1.292
|
-5.022
|
Operating Margin
|
-
|
-
|
-
|
-
|
-1,064.38%
|
-215.9%
|
Earnings before Tax (EBT)
1 |
-0.9899
|
-3.898
|
-5.291
|
-1.976
|
-8.514
|
-5.144
|
Net income
1 |
-0.9949
|
-3.903
|
-5.261
|
-1.976
|
-8.404
|
-5.143
|
Net margin
|
-
|
-
|
-
|
-
|
-6,922.02%
|
-221.11%
|
EPS
2 |
-0.2590
|
-0.6113
|
-0.5403
|
-0.1880
|
-0.7916
|
-0.4816
|
Free Cash Flow
1 |
-0.1835
|
1.632
|
1.179
|
0.0512
|
-2.787
|
-0.1615
|
FCF margin
|
-
|
-
|
-
|
-
|
-2,295.42%
|
-6.94%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
17-05-01
|
18-04-30
|
19-04-30
|
20-05-29
|
21-05-31
|
22-05-02
|
Fiscal Period: December |
2016
|
2017
|
2018
|
2019
|
2020
|
2021
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
1.47
|
Net Cash position
1 |
0.11
|
4.85
|
7
|
3.06
|
0.17
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-0.2999
x
|
Free Cash Flow
1 |
-0.18
|
1.63
|
1.18
|
0.05
|
-2.79
|
-0.16
|
ROE (net income / shareholders' equity)
|
601%
|
-93.4%
|
-45.9%
|
-13.6%
|
-77.1%
|
-96.4%
|
ROA (Net income/ Total Assets)
|
-292%
|
-70.2%
|
-29.1%
|
-5.57%
|
-6.64%
|
-40.5%
|
Assets
1 |
0.3411
|
5.558
|
18.08
|
35.51
|
126.6
|
12.69
|
Book Value Per Share
2 |
-0.0300
|
0.9600
|
1.440
|
1.390
|
0.7000
|
0.3100
|
Cash Flow per Share
2 |
0.0100
|
0.4300
|
0.5300
|
0.1500
|
0.1000
|
0.0200
|
Capex
1 |
0.02
|
-
|
-
|
-
|
0.01
|
0.01
|
Capex / Sales
|
-
|
-
|
-
|
-
|
6.62%
|
0.34%
|
Announcement Date
|
17-05-01
|
18-04-30
|
19-04-30
|
20-05-29
|
21-05-31
|
22-05-02
|
|
1st Jan change
|
Capi.
|
---|
| -.--% | 1.83M | | +37.65% | 6.04B | | -19.68% | 4.27B | | +4.49% | 3.28B | | -15.69% | 2.96B | | -5.64% | 2.43B | | +44.89% | 1.93B | | -12.71% | 1.59B | | -4.27% | 1.58B | | -14.86% | 1.5B |
Alternative Medicine
|